Clinical implementation of 177Lu-PSMA-617 (LuPSMA) at a major academic center: Initial experiences.

被引：0
|
作者：
Ravi, Praful
Kelly, Emma
Whelpley, Bridget
Choudhury, Atish Dipankar
Sunkara, Rajitha
Pomerantz, Mark
Taplin, Mary-Ellen
Kilbridge, Kerry L.
Wei, Xiao X.
Morgans, Alicia K.
Bizzo, Renata Rocha de Almeida
Wolanski, Andrew
Jacene, Heather
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Brigham & Womens Hosp, Boston, MA USA
[3] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
108
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions
    Wang, Jingnan
    Zang, Jie
    Wang, Hao
    Liu, Qingxing
    Li, Fang
    Lin, Yansong
    Huo, Li
    Jacobson, Orit
    Niu, Gang
    Fan, Xinrong
    Zhu, Zhaohui
    Chen, Xiaoyuan
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (06) : 431 - 438
  • [32] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
    Rahbar, Kambiz
    Boegemann, Martin
    Ahmadzadehfar, Hojjat
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 166 - 167
  • [33] 177Lu-PSMA-617 for metastatic prostate cancer: aiming for the right spot
    Mateo, Joaquin
    Zurita, Amado J.
    LANCET, 2024, 404 (10459): : 1174 - 1176
  • [34] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
    Kambiz Rahbar
    Martin Bögemann
    Hojjat Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 166 - 167
  • [35] A single-center experience in compassionate use of 177Lu-PSMA-617 in advanced prostate cancer.
    Crosta, G.
    Argiroffi, G.
    Lorenzoni, A.
    Kirienko, M.
    Aliberti, G.
    Rubino, F.
    Chiesa, C.
    Procopio, G.
    Guadalupi, V.
    Verzori, E.
    Maccauro, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S677 - S678
  • [36] Activity of 177Lu-PSMA-617 in Patients With Advanced Prostate Cancer and Brain Metastases
    Rashid, Narmeen S.
    Rami, Avina
    Lang, Min
    Stoltenberg, Hailey
    Wolanski, Andrew
    Ritzer, Jolivette
    Jacene, Heather
    Ravi, Praful
    CLINICAL GENITOURINARY CANCER, 2025, 23 (02)
  • [37] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response Reply
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Tripathi, Madhavi
    Bal, Chandrasekhal
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 168 - 169
  • [38] 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
    Kambiz Rahbar
    Hojjat Ahmadzadehfar
    Martin Boegemann
    European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 513 - 514
  • [39] Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma
    Jueptner, Michael
    Marx, Marlies
    Zuhayra, Maaz
    Luetzen, Ulf
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2019, 58 (04): : 328 - 330
  • [40] 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Boegemann, Martin
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (03) : 513 - 514
12345